CSIMarket
 
Ocugen Inc   (OCGN)
Other Ticker:  
 
 
Price: $1.0800 $0.06 5.882%
Day's High: $1.09 Week Perf: 14.61 %
Day's Low: $ 1.02 30 Day Perf: 61.92 %
Volume (M): 3,618 52 Wk High: $ 1.28
Volume (M$): $ 3,907 52 Wk Avg: $0.57
Open: $1.05 52 Wk Low: $0.35



 Market Capitalization (Millions $) 277
 Shares Outstanding (Millions) 256
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -76
 Cash Flow (TTM) (Millions $) -48
 Capital Exp. (TTM) (Millions $) 10

Ocugen Inc
Ocugen Inc. is a biopharmaceutical company based in the United States that specializes in developing gene therapies to treat rare inherited eye diseases. The company's main focus is on developing a potential cure for blindness-causing diseases, such as Retinitis Pigmentosa and Leber Congenital Amaurosis. Ocugen Inc. utilizes its own proprietary technology platform, known as OcuGene, to create gene therapies that aim to correct or replace defective genes in the eye. The company is actively involved in conducting clinical trials to evaluate the safety and efficacy of its gene therapies. Ocugen Inc. also collaborates with various research institutions and partners to advance its pipeline of therapeutic candidates.


   Company Address: 11 Great Valley Parkway Malvern 19355 PA
   Company Phone Number: 328-4701   Stock Exchange / Ticker: NASDAQ OCGN
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Management Changes

Ocugen Inc. Appoints Dr. Huma Qamar as Chief Medical Officer Amidst Strong Market Performance and Promising Growth Prospects

Published Mon, Mar 18 2024 10:31 AM UTC


In a strategic move to strengthen its position in the biotechnology industry, Ocugen Inc. (NASDAQ: OCGN) has recently appointed Dr. Huma Qamar as its new Chief Medical Officer (CMO). The addition of Dr. Qamar to the Ocugen team is expected to further accelerate the company's mission of discovering, developing, and commercializing innovative gene and cell therapies as we...

Clinical Study

Ocugen's OCU410 Gene Therapy Advances as Phase 1/2 Clinical Trial Dosing Completes, Paving the Way for Potential Breakthrough in Geographic Atrophy Treatment

Published Wed, Mar 13 2024 12:01 PM UTC

Dosing Completion of Phase 1/2 Clinical Trial for OCU410 Gene Therapy Candidate in Geographic Atrophy Signals Progress for OcugenOcugen, Inc. (NASDAQ: OCGN), a biotechnology company specialized in gene and cell therapies as well as vaccines, has announced the completion of dosing for the first cohort in its Phase 1/2 ArMaDa clinical trial. This trial is evaluating the safet...

Product Service News

Ocugen Clinical Showcase Webcast Highlights Promising Advances in Gene and Cell Therapies and Vaccines

Published Wed, Feb 28 2024 1:01 PM UTC

Ocugen, Inc. (NASDAQ: OCGN), a leading biotechnology company dedicated to the development and commercialization of innovative gene and cell therapies and vaccines, recently announced the availability of its Clinical Showcase webcast on February 21, 2024. This noteworthy event shed light on the cutting-edge advancements in Ocugen's research and development efforts. In this ar...

Clinical Study

Ocugen, Inc. Completes Dosing in First Cohort of Phase 1/2 Clinical Trial for OCU410ST in Stargardt Disease

Published Thu, Feb 22 2024 9:05 PM UTC

Ocugen, Inc., a biotechnology company dedicated to the development of gene and cell therapies and vaccines, recently announced the completion of dosing in the first cohort of its Phase 1/2 clinical trial for OCU410ST, a modifier gene therapy candidate for Stargardt disease. Stargardt disease, an orphan blindness disease, affects approximately 35,000 individuals in the Unite...

Product Service News

Ocugen's CEO Dr. Shankar Musunuri to Highlight Future Innovations in Healthcare at Pharma Market Research Conference 2024

Published Wed, Jan 31 2024 1:01 PM UTC

In what is a landmark development, Ocugen, Inc., a trailblazer in the biotechnology industry specializing in novel gene and cell therapies, has announced its entry on the stage of the Pharma Market Research Conference (PMRC) 2024. The announcement comes straight from the company's headquarters in Malvern, PA., and has been eagerly anticipated by stakeholders in the pharmaceu...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com